Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India.

doi:10.1186/s13048-026-02021-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India.

Journal of ovarian research - 7 Feb 2026

Yeshala Susheel Kumar, Panda Soumya Surath, Moharana Lalatendu, Saju S V, Rathinam Krishnakumar, Raju Susan Honey, Sehrawat Amit, Sundriyal Deepak, Phillip Ashwin Oommen, Kinsely Pamela Alice, Bhatia Kanu Priya, Kayal Smita, Dubashi Biswajit, Cyriac Sunu Lazar, Natarajan Sathya, Samantaray Lipsita, Mohanty Swati Sucharita, Sadangi Sudam, Pradhan Snehasis, Rana Arti, Ganesan Prasanth

Abstract excerpt

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a significant advancement in the maintenance treatment of advanced High-Grade Serous Ovarian Cancer (HGSOC), particularly in patients with BRCA mutations or Homologous Recombination Deficiency (HRD). While randomized trials have demonstrated their efficacy, real-world evidence from low- and middle-income countries (LMIC) like India...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to India

Share to Indoles

Share to Ovarian Neoplasms

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41654913
DOI: 10.1186/s13048-026-02021-0
PMCID: PMC12977420

Genes

BRCA2
HGS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India.PMID 41654913Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: An overview of the practice‐changing trialsSemantic proximity Read ↗

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studySemantic proximity Read ↗

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.Semantic proximity Read ↗

Frontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched populationSemantic proximity Read ↗

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA MutationsSemantic proximity Read ↗

PARP inhibitors: a tsunami of indications in different malignancies.Semantic proximity Read ↗

Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer.Semantic proximity Read ↗

The HRD Decision-Which PARP Inhibitor to Use for Whom and When.Semantic proximity Read ↗

PARP Inhibitors in Ovarian CancerSemantic proximity Read ↗

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.